A Phase 1 Study of the Safety, Pharmacokinetics, and Biological Activity of Metronomic Dosing With Orally Administered Vinorelbine Tablets in Subjects With Non-Hematologic Malignancies For Which There Are No Currently Accepted Therapies
The purpose of this study is to determine the safety of oral administration of vinorelbine once daily for at least 7 days. The study will be conducted in subjects with a non-hematologic malignancy for which there are no currently accepted therapies.
100 Clinical Results associated with Metronome Therapeutics, Inc.
0 Patents (Medical) associated with Metronome Therapeutics, Inc.
100 Deals associated with Metronome Therapeutics, Inc.
100 Translational Medicine associated with Metronome Therapeutics, Inc.